ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Mankind Pharma announced the successful passing of a special resolution to appoint Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The Postal Ballot concluded with the required majority.
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma announced that members of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), approved its voluntary liquidation in an EGM.
Mankind Pharma has allotted 49,112 equity shares under its ESOP Plan 2022 to eligible employees upon exercise of options. The allotment increases its paid-up share capital.
Mankind Pharma has allotted 49,112 equity shares under its ESOP scheme. This allotment increases the paid-up share capital by Rs. 49,112 in face value.
Mankind Pharma announced the cessation of Mr. Bharat Anand as an Independent Director, effective August 30, 2026, upon the completion of his second term.
Mankind Pharma's board approved the voluntary liquidation of its subsidiary, Bharat Serums and Vaccines Limited, to integrate its business into the parent company.
Mankind Pharma has received an improved ESG rating of 64 from CRISIL, categorized as 'Strong'. The rating was assigned independently without company engagement.
Mankind Pharma entered an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd. The deal covers commercialisation of insulin analogues in India.
Mankind Pharma Limited has issued a Postal Ballot Notice to seek shareholder approval for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director.
Mankind Pharma has completed the realignment of security cover for its NCDs. Consequently, it has released the pledge on 28,280 shares of Bharat Serums and Vaccines.
Mankind Pharma has incorporated a wholly-owned subsidiary in the Netherlands, "Mankind Pharma (Netherlands) B.V.", with an issued capital of ₹55.06 Crore.
Mankind Pharma has incorporated a wholly-owned subsidiary, 'Mankind Pharma (Netherlands) B.V.', in the Netherlands as previously disclosed.
Mankind Pharma has appointed Mr. Anish Vanraj Bafna as an Additional Director (Non-Executive Independent Director), effective August 10, 2026.